Ampio Pharmaceuticals, Inc.
AMPE · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | 0.19 | -0.31 |
| FCF Yield | -516.39% | -824.60% | -12.49% | -5.38% |
| EV / EBITDA | 0.26 | 0.40 | -5.06 | -17.74 |
| Quality | ||||
| ROIC | -252.47% | -81.73% | -43.87% | -77.06% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 1.29 | 0.83 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 59.47% | -48.94% | 4.10% | 3.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.51 | 2.05 | 1.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 15.19 | 4.43 |
| Cash Conversion Cycle | -1,095.00 | -17.03 | -118.44 | 24.79 |